skip to content
Thank you for visiting First Coast Service Options' Medicare provider website. This website is intended exclusively for Medicare providers and health care industry professionals to find the latest Medicare news and information affecting the provider community.
To enable us to present you with customized content that focuses on your area of interest, please select your preferences below:
Select which best describes you:
Select your location:
Select your line of business:

By clicking Continue below you agree to the following:

LICENSE FOR USE OF "PHYSICIAN'S CURRENT PROCEDURAL TERMINOLOGY" (CPT), FOURTH EDITION End User/Point and Click Agreement: CPT codes, descriptions and other data only are copyright 2022 American Medical Association (AMA).

All Rights Reserved (or such other date of publication of CPT). CPT is a trademark of the AMA.
You, your employees, and agents are authorized to use CPT only as contained in the following authorized materials:
Local Coverage Determinations (LCDs),
Local Medical Review Policies (LMRPs),
Bulletins/Newsletters,
Program Memoranda and Billing Instructions,
Coverage and Coding Policies,
Program Integrity Bulletins and Information,
Educational/Training Materials,
Special mailings,
Fee Schedules;

internally within your organization within the United States for the sole use by yourself, employees and agents. Use is limited to use in Medicare, Medicaid, or other programs administered by the Centers for Medicare and Medicaid Services (CMS), formerly known as Health Care Financing Administration (HCFA). You agree to take all necessary steps to insure that your employees and agents abide by the terms of this agreement. Any use not authorized herein is prohibited, including by way of illustration and not by way of limitation, making copies of CPT for resale and/or license, transferring copies of CPT to any party not bound by this agreement, creating any modified or derivative work of CPT, or making any commercial use of CPT. License to use CPT for any use not authorized here in must be obtained through the AMA, CPT Intellectual Property Services, 515 N. State Street, Chicago, IL 60610. Applications are available at the AMA website. Applicable FARS/DFARS restrictions apply to government use.

AMA Disclaimer of Warranties and Liabilities CPT is provided "as is" without warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability and fitness for a particular purpose. No fee schedules, basic unit, relative values or related listings are included in CPT. The AMA does not directly or indirectly practice medicine or dispense medical services. The responsibility for the content of this file/product is with CMS and no endorsement by the AMA is intended or implied. The AMA disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this file/product. This agreement will terminate upon notice if you violate its terms. The AMA is a third party beneficiary to this agreement.

CMS Disclaimer: The scope of this license is determined by the AMA, the copyright holder. Any questions pertaining to the license or use of the CPT must be addressed to the AMA. End Users do not act for or on behalf of the CMS. CMS DISCLAIMS RESPONSIBILITY FOR ANY LIABILITY ATTRIBUTABLE TO END USER USE OF THE CPT. CMS WILL NOT BE LIABLE FOR ANY CLAIMS ATTRIBUTABLE TO ANY ERRORS, OMISSIONS, OR OTHER INACCURACIES IN THE INFORMATION OR MATERIAL CONTAINED ON THIS PAGE. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

AMA - U.S. Government Rights

This product includes CPT which is commercial technical data and/or computer data bases and/or commercial computer software and/or commercial computer software documentation, as applicable which were developed exclusively at private expense by the American Medical Association, 515 North State Street, Chicago, Illinois, 60610. U.S. Government rights to use, modify, reproduce, release, perform, display, or disclose these technical data and/or computer data bases and/or computer software and/or computer software documentation are subject to the limited rights restrictions of DFARS 252.227-7015(b)(2)(June 1995) and/or subject to the restrictions of DFARS 227.7202-1(a)(June 1995) and DFARS 227.7202-3(a )June 1995), as applicable for U.S. Department of Defense procurements and the limited rights restrictions of FAR 52.227-14 (June 1987) and/or subject to the restricted rights provisions of FAR 52.227-14 (June 1987) and FAR 52.227-19 (June 1987), as applicable, and any applicable agency FAR Supplements, for non-Department Federal procurements.

ADA CURRENT DENTAL TERMINOLOGY, (CDT)
End User/Point and Click Agreement: These materials contain Current Dental Terminology (CDTTM), Copyright © 2016 American Dental Association (ADA). All rights reserved. CDT is a trademark of the ADA.

THE LICENSE GRANTED HEREIN IS EXPRESSLY CONDITIONED UPON YOUR ACCEPTANCE OF ALL TERMS AND CONDITIONS CONTAINED IN THIS AGREEMENT. BY CLICKING ON THE BUTTON LABELED "ACCEPT", YOU HEREBY ACKNOWLEDGE THAT YOU HAVE READ, UNDERSTOOD AND AGREED TO ALL TERMS AND CONDITIONS SET FORTH IN THIS AGREEMENT.

IF YOU DO NOT AGREE WITH ALL TERMS AND CONDITIONS SET FORTH HEREIN, CLICK ON THE BUTTON LABELED "DECLINE" AND EXIT FROM THIS COMPUTER SCREEN.

IF YOU ARE ACTING ON BEHALF OF AN ORGANIZATION, YOU REPRESENT THAT YOU ARE AUTHORIZED TO ACT ON BEHALF OF SUCH ORGANIZATION AND THAT YOUR ACCEPTANCE OF THE TERMS OF THIS AGREEMENT CREATES A LEGALLY ENFORCEABLE OBLIGATION OF THE ORGANIZATION. AS USED HEREIN, "YOU" AND "YOUR" REFER TO YOU AND ANY ORGANIZATION ON BEHALF OF WHICH YOU ARE ACTING.

Subject to the terms and conditions contained in this Agreement, you, your employees and agents are authorized to use CDT only as contained in the following authorized materials and solely for internal use by yourself, employees and agents within your organization within the United States and its territories. Use of CDT is limited to use in programs administered by Centers for Medicare & Medicaid Services (CMS). You agree to take all necessary steps to ensure that your employees and agents abide by the terms of this agreement. You acknowledge that the ADA holds all copyright, trademark and other rights in CDT. You shall not remove, alter, or obscure any ADA copyright notices or other proprietary rights notices included in the materials.

Any use not authorized herein is prohibited, including by way of illustration and not by way of limitation, making copies of CDT for resale and/or license, transferring copies of CDT to any party not bound by this agreement, creating any modified or derivative work of CDT, or making any commercial use of CDT. License to use CDT for any use not authorized herein must be obtained through the American Dental Association, 211 East Chicago Avenue, Chicago, IL 60611. Applications are available at the ADA website.

Applicable Federal Acquisition Regulation Clauses (FARS)\Department of restrictions apply to Government Use.

ADA DISCLAIMER OF WARRANTIES AND LIABILITIES: CDT is provided "as is" without warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability and fitness for a particular purpose. No fee schedules, basic unit, relative values or related listings are included in CDT. The ADA does not directly or indirectly practice medicine or dispense dental services. The sole responsibility for the software, including any CDT and other content contained therein, is with (insert name of applicable entity) or the CMS; and no endorsement by the ADA is intended or implied. The ADA expressly disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this file/product. This Agreement will terminate upon notice to you if you violate the terms of this Agreement. The ADA is a third party beneficiary to this Agreement.

CMS DISCLAIMER: The scope of this license is determined by the ADA, the copyright holder. Any questions pertaining to the license or use of the CDT should be addressed to the ADA. End Users do not act for or on behalf of the CMS. CMS DISCLAIMS RESPONSIBILITY FOR ANY LIABILITY ATTRIBUTABLE TO END USER USE OF THE CDT. CMS WILL NOT BE LIABLE FOR ANY CLAIMS ATTRIBUTABLE TO ANY ERRORS, OMISSIONS, OR OTHER INACCURACIES IN THE INFORMATION OR MATERIAL COVERED BY THIS LICENSE. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

End Disclaimer


This website provides information and news about the Medicare program for health care professionals only. All communication and issues regarding your Medicare benefits are handled directly by Medicare and not through this website. For the most comprehensive experience, we encourage you to visit Medicare.gov or call 1-800-MEDICARE. In the event your provider fails to submit your Medicare claim, please view these resources for claim assistance.
Join eNews       En Español
Text Size:
YouTube LinkedIn Email Print
Close
Send a link to this page
[Multiple email addresses must be separated by a semicolon.]
Last Modified: 4/30/2025 Location: FL, PR, USVI Business: Part A, Part B

NCD 110.24: Chimeric Antigen Receptor (CAR) T-cell therapy -- billing instructions

This article provides billing information and instructions to providers regarding CAR T-cell therapy. The article was updated on January 19, 2023, to add details regarding the new approved CAR T-cell product Carvykti as well as Part B (outpatient) billing instructions and pricing information effective for dates of service (DOS) on and after January 1, 2022.

Overview

Effective for DOS on or after August 7, 2019, CMS will cover the treatment for cancer with autologous T-cells expressing at least one CAR when administered at an FDA Risk Evaluation and Mitigation Strategies (REMS) approved facility. Coverage guidelines and limitations regarding the new national coverage determination (NCD) for CAR T-cell therapy are detailed in MLN Matters article MM12177 external pdf file and MM12928 external pdf file.
First Coast and other A/B MACs have editing only allowing CAR T-cell therapy services to be submitted by or performed in an FDA REMS approved facility. Prior to submitting Part A claims, inform First Coast when the REMS facility has been approved, along with the facility number. This will assist with the prevention of unnecessary claim denials. Providing this information prior to claim submission allows First Coast to update the Part A editing accordingly.
Additionally, routine costs in qualifying clinical trials using CAR T-cell therapy as an investigational agent meeting the requirements listed in NCD 310.1 will be covered effective August 7, 2019. MM12177 details situations in which T-cell therapy are not covered.
Note: The use of allogenic T-cells from healthy donors are not autologous CAR T-cell treatments and should not be billed as autologous CAR T-cell treatments.

Key topic links

list item Billing and coding CAR T-cell therapy for inpatient services
list item Billing and coding CAR T-cell therapy for outpatient services
list item Billing and pricing for Part B (outpatient) claims
list item Additional information
list item Medicare Advantage claims

Billing and coding CAR T-cell therapy for inpatient services

Effective for claims with DOS on or after August 7, 2019, First Coast will recognize for inpatient claims the following ICD-10-PCS codes for CAR T-cell therapy. Be sure to indicate the name of the CAR T-cell product the beneficiary receives in the ‘Remarks’ field on Claim Entry page 4 (MAP1714).. Your claims could be delayed if this information is not included.
In addition to requiring specific diagnoses for each CAR T-cell product, First Coast and other A/B MACs also created Part A editing for the following ICD-10-PCS codes that only allows CAR T-cell therapy services to be submitted by or performed in an FDA REMS approved facility.

Product name
For dates of discharge
Immunotherapy approach
ICD-10 PCS code
Obe-cel/Aucatzyl
On and after November 8, 2024
Via peripheral vein
XW0338A - Introduction of Obecabtagene autoleucel into peripheral vein, percutaneous approach, new technology group 10
Obe-cel/Aucatzyl
On and after November 8, 2024
Through central vein
XW0438A - Introduction of Obecabtagene autoleucel into central vein, percutaneous approach, new technology group 10
Carvykti
On and after February 28, 2022
Via peripheral vein
XW033A7 -- Carvykti: Introduction of ciltacabtagene autoleucel into peripheral vein, percutaneous approach, new technology group 7
Carvykti
On and after February 28, 2022
Through central vein
XW043A7 - Carvykti: Introduction of ciltacabtagene autoleucel into central vein, percutaneous approach, new technology group 7
Yescarta
On and after October 1, 2021
Via peripheral vein
XW033H7 -- Yescarta: Introduction of axicabtagene ciloleucel immunotherapy into peripheral vein, percutaneous approach, new technology group 7
Yescarta
On and after October 1, 2021
Through central vein
XW043H7 -- Yescarta: Introduction of axicabtagene ciloleucel immunotherapy into central vein, percutaneous approach, new technology group 7
Kymriah
On and after October 1, 2021
Via peripheral vein
XW033J7 -- Kymriah: Introduction of tisagenlecleucel immunotherapy into peripheral vein, percutaneous approach, new technology group 7
Kymriah
On and after October 1, 2021
Through central vein
XW043J7 -- Kymriah: Introduction of tisagenlecleucel immunotherapy into central vein, percutaneous approach, new technology group 7
ABECMA
On and after October 1, 2021
Via peripheral vein
XW033K7 -- ABECMA: Introduction of idecabtagene vicleucel immunotherapy into peripheral vein, percutaneous approach, new technology group 7
ABECMA
On and after October 1, 2021
Through central vein
XW043K7 -- ABECMA: Introduction of idecabtagene vicleucel immunotherapy into central vein, percutaneous approach, new technology group 7
Tecartus
On and after October 1, 2021
Via peripheral vein
XW033M7 -- Tecartus: Introduction of brexucabtagene autoleucel immunotherapy into peripheral vein, percutaneous approach, new technology group 7
Tecartus
On and after October 1, 2021
Through central vein
XW043M7 -- Tecartus: Introduction of brexucabtagene autoleucel immunotherapy into central vein, percutaneous approach, new technology group 7
Breyanzi
On and after October 1, 2021
Via peripheral vein
XW033N7 -- Breyanzi: Introduction of lisocabtagene maraleucel immunotherapy into peripheral vein, percutaneous approach, new technology group 7
Breyanzi
On and after October 1, 2021
Through central vein
XW043N7 -- Breyanzi: Introduction of lisocabtagene maraleucel immunotherapy into central vein, percutaneous approach, new technology group 7
FDA approved products awaiting their own PCS code and products used in qualifying clinical trials
On and after October 1, 2021
Via peripheral vein
XW033C7 -- FDA approved products awaiting their own PCS code: Introduction of autologous engineered chimeric antigen receptor t-cell immunotherapy into peripheral vein, percutaneous approach, new technology group 7
FDA approved products awaiting their own PCS code and products used in qualifying clinical trials
On and after October 1, 2021
Through central vein
XW043C7 -- FDA approved products awaiting their own PCS code: Introduction of autologous engineered chimeric antigen receptor t-cell immunotherapy into central vein, percutaneous approach, new technology group 7
Note: Since allogenic T-cells are not autologous CAR T-cells, it is inappropriate to use any of the above autologous CAR T-cell ICD-10- PCS procedure codes for allogenic T-cell treatments.
Use the following revenue codes for billing inpatient CAR T-cell therapy services:
• 0871 -- Cell Collection
• 0872 -- Specialized Biologic Processing and Storage, Prior to Transport
• 0873 -- Storage and Processing after Receipt of Cells from Manufacturer
• 0874 -- Infusion of Modified Cells
• 0891 -- Special Processed Drugs -- FDA Approved Cell Therapy
Clinical trials
Medicare contractors will not require NCD 110.24 REMS facility and diagnosis codes for autologous CAR T-cell therapy ICD-10-PCS codes in the chart above in qualifying clinical trials under NCD 310.1 billed with the national clinical trial (NCT) number for the specific trial, condition code (CC) 30, value code (VC) D4, and the ICD-10 code Z00.6 clinical trial diagnosis code effective for DOS on or after October 1, 2021.
Medicare contractors will reject claims for allogeneic CAR T-cell therapy ICD-10-PCS codes XW033G7 and XW043G7, and autologous CAR T-cell therapy ICD-10-PCS codes XW033C7 and XW043C7, when not billed for qualifying clinical trials under NCD 310.1 with the NCT number for the specific trial, CC 30, VC D4, and ICD-10 code Z00.6 clinical trial diagnosis code effective for DOS on or after October 1, 2021.
To notify the MAC of a case where the CAR T-cell therapy product is purchased in the usual manner, but the case involves a clinical trial of a different product (and ICD-10-CM diagnosis code Z00.6 is on the claim), the provider may enter a Billing Note NTE02 “Diff Prod Clin Trial” on the electronic claim 837I or a remark “Diff Prod Clin Trial” on a paper claim. The processing system will auto-populate the payer-only condition code “ZC” so the Pricer will not apply the payment adjustment in calculating the payment for the case. See MM11879 external pdf file , MM13734 external pdf file and change request (CR) 13926 external pdf file for details.
list item Return to key topic links list list item

Billing and coding CAR T-cell therapy for outpatient services

Effective for DOS on or after August 7, 2019:
• Medicare will pay claims from approved providers for administration of autologous T-cells expressing at least one CAR for the treatment for cancer.
• In addition to requiring specific diagnoses for each CAR T-cell product and administration, First Coast and other A/B MACs will create editing for the HCPCS codes in the chart below that only allows CAR T-cell therapy services to be submitted by or performed in an FDA REMS approved facility.
• Medicare Part A will recognize, for outpatient prospective payment system (OPPS) and critical access hospital (CAH) claims, the following HCPCS codes for CAR T-cell therapy in the chart below. Be sure to indicate the name of the CAR T-cell product the beneficiary receives in the ‘Remarks’ field on Claim Entry page 4 (MAP1714) of the electronic claim.
Effective for claims with DOS on or after January 1, 2022:
• Medicare Part B will recognize the following HCPCS codes in the chart below for CAR T-cell therapy for place of service (POS) 11 (office) or 49 (independent clinic) claims.
• For Part B unclassified drugs or biologicals, be sure to indicate the name of the CAR T-cell product the beneficiary receives in Item 19 of the CMS-1500 (or the electronic equivalent). Your claims could be delayed if this information is not included.

Procedure or drug product
Applicable DOS
CPT/ HCPCS
Payable or Not payable
Rationale
Additional Notes
The administration*
Effective January 1, 2025-current
38228*
Payable in Part A and B outpatient.
Not payable in ASC.
CAR T-cell therapy is not allowed in an ASC.
*Note: For Part B (outpatient claims), CPT code 38228 is only payable when the line item has a KX modifier appended.
The administration*
Effective August 7, 2019-December 31, 2024
0540T*
Payable in Part A and B outpatient.
Not payable in ASC.
CAR T-cell therapy is not allowed in an ASC.
*Note: For Part B (outpatient claims), CPT code 0540T is only payable when the line item has a KX modifier appended.
Axicabtagene ciloleucel (Yescarta)*
Effective August 7, 2019-current
Q2041*
Payable in Part A and B outpatient.
Not payable in ASC.
HCPCS code Q2041 has an ASC payment indicator "B5" (Alternative code may be available, no payment made).
CAR T-cell therapy is not allowed in an ASC.
*Note: For Part B (outpatient claims), HCPCS code Q2041 is only payable when the line item has a KX modifier appended.
Tisagenlecleucel (Kymriah)*
Effective August 7, 2019-current
Q2042*
Payable in Part A and B outpatient.
Not payable in ASC.
HCPCS code Q2042 has an ASC payment indicator "B5" (Alternative code may be available, no payment made).
CAR T-cell therapy is not allowed in an ASC
Note: For Part B (outpatient claims), HCPCS code Q2042 is only payable when the line item has a KX modifier appended.
Brexucabtagene Autoleucel (Tecartus)*
Effective April 1, 2021-current
Q2053*
Payable in Part A and B outpatient.
Not payable in ASC.
CAR T-cell therapy is not allowed in an ASC.
HCPCS code Q2053 is invalid in the ASC setting.
*Note: For Part B (outpatient claims), HCPCS code Q2053 is only payable when the line item has a KX modifier appended.
Brexucabtagene Autoleucel (Tecartus)*
Effective July 24, 2020-March 31, 2021
J3490, J3590, or J9999*
Payable in Part B.
Packaged in Part A outpatient.
Code should not be billed by ASCs.
  
Code is used by Part B providers (not ASC) to report this product.
*Note: For Part B (outpatient claims), HCPCS codes J3490, J3590 and J9999 are only payable when the line item has a KX modifier appended.
Brexucabtagene Autoleucel (Tecartus)
Effective January 1, 2021-March 31, 2021
C9073
Not payable in Part B.
Payable in Part A outpatient.
Not payable in ASC.
HCPCS code C9073 has an ASC payment indicator "B5" (Alternative code may be available, no payment made).
CAR T-cell therapy is not allowed in an ASC.
HCPCS code is non-payable on Part B provider claims.
Code is used by Part A outpatient and ASCs (not Part B providers) to report this product.
Brexucabtagene Autoleucel (Tecartus)
Effective July 24, 2020-December 31, 2020
C9399
Not payable in Part B.
Payable in Part A outpatient.
Not payable in ASC.
CAR T-cell therapy is not allowed in an ASC.
HCPCS code is non-payable on Part B provider claims.
Code is used by Part A outpatient and ASCs (not Part B providers) to report this product.
Lisocabtagene maraleucel (Breyanzi)*
Effective October 1, 2021-current
Q2054*
Payable in Part A and B outpatient.
Not payable in ASC.
CAR T-cell therapy is not allowed in an ASC.
HCPCS code Q2054 is invalid in the ASC setting.
*Note: For Part B (outpatient claims), HCPCS code Q2054 is only payable when the line item has a KX modifier appended.
Lisocabtagene maraleucel (Breyanzi)*
Effective February 5, 2021-September 30, 2021
J3490, J3590, or J9999*
Payable in Part B.
Packaged in Part A outpatient.
Code should not be billed by ASCs.
  
Code is used by Part B providers (not ASC) to report this product.
*Note: For Part B (outpatient claims), HCPCS codes J3490, J3590 and J9999 are only payable when the line item has a KX modifier appended.
Lisocabtagene maraleucel (Breyanzi)
Effective July 1, 2021-September 30, 2021
C9076
Not payable in Part B.
Payable in Part A outpatient.
Not payable in ASC.
CAR T-cell therapy is not allowed in an ASC.
HCPCS code C9076 is invalid in the ASC setting.
HCPCS code is non-payable on Part B provider claims.
Code is used by Part A outpatient and ASCs (not Part B providers) to report this product.
Lisocabtagene maraleucel (Breyanzi)
Effective February 5, 2021-June 30, 2021
C9399
Not payable in Part B.
Payable in Part A outpatient.
Not payable in ASC.
CAR T-cell therapy is not allowed in an ASC.
HCPCS code is non-payable on Part B provider claims.
Code is used by Part A outpatient and ASCs (not Part B providers) to report this product.
Idecabtagene vicleucel (Abecma)*
Effective January 1, 2022-current
Q2055*
Payable in Part A and B outpatient.
Not payable in ASC.
CAR T-cell therapy is not allowed in an ASC.
HCPCS code Q2055 is invalid in the ASC setting.
*Note: For Part B (outpatient claims), HCPCS code Q2055 is only payable when the line item has a KX modifier appended.
Idecabtagene vicleucel (Abecma)*
Effective March 26, 2021-December 31, 2021
J3490, J3590, or J9999*
Payable in Part B.
Packaged in Part A outpatient.
Code should not be billed by ASCs.
Code is used by Part B providers (not ASC) to report this product.
*Note: For Part B (outpatient claims), HCPCS codes J3490, J3590 and J9999 are only payable when the line item has a KX modifier appended.
Idecabtagene vicleucel (Abecma)
Effective October 1, 2021-December 31, 2021
C9081
Not payable in Part B.
Payable in Part A outpatient.
Not payable in ASC.
HCPCS code C9081 has an ASC payment indicator "B5" (Alternative code may be available, no payment made)
CAR T-cell therapy is not allowed in an ASC.
HCPCS code is non-payable on Part B provider claims.
Code is used by Part A outpatient and ASCs (not Part B providers) to report this product.
Idecabtagene vicleucel (Abecma)
Effective March 21, 2021-September 30, 2021
C9399
Not payable in Part B.
Payable in Part A outpatient.
Not payable in ASC.
CAR T-cell therapy is not allowed in an ASC.
HCPCS code is non-payable on Part B provider claims.
Code is used by Part A outpatient and ASCs (not Part B providers) to report this product.
Ciltacabtagene autoleucel (Carvykti)*
Effective October 1, 2022-current
Q2056*
Payable in Part A and B outpatient.
Not payable in ASC.
CAR T-cell therapy is not allowed in an ASC.
HCPCS code Q2056 is invalid in the ASC setting.
*Note: For Part B (outpatient claims), HCPCS code Q2056 is only payable when the line item has a KX modifier appended.
Ciltacabtagene autoleucel (Carvykti)
Effective July 1, 2022-September 30, 2022
C9098
Not payable in Part B.
Payable in Part A outpatient.
Not payable in ASC.
CAR T-cell therapy is not allowed in an ASC.
HCPCS code C9098 is invalid in the ASC setting.
HCPCS code is non-payable on Part B provider claims.
Code is used by Part A outpatient and ASCs (not Part B providers) to report this product.
Ciltacabtagene autoleucel (Carvykti)
Effective February 28, 2022- June 30, 2022
C9399
Not payable in Part B.
Payable in Part A outpatient.
Not payable in ASC.
CAR T-cell therapy is not allowed in an ASC.
HCPCS code is non-payable on Part B provider claims.
Code is used by Part A outpatient and ASCs (not Part B providers) to report this product.
Ciltacabtagene autoleucel (Carvykti)*
Effective February 28, 2022- September 30, 2022
J3490, J3590, or J9999*
Payable in Part B.
Packaged in Part A outpatient.
Code should not be billed by ASCs.
  
Code is used by Part B providers (not ASC) to report this product.
*Note: For Part B (outpatient claims), HCPCS codes J3490, J3590 and J9999 are only payable when the line item has a KX modifier appended.
Obe-cel/ AUCATZYL® (Obecabtagene Autoleucel)
Effective November 8, 2024 - current
C9399
Not payable in Part B.
Payable in Part A outpatient.
Not payable in ASC
CAR T-cell therapy is not allowed in an ASC.
HCPCS code is non-payable on Part B provider claims.
Code is used by Part A outpatient and ASCs (not Part B providers) to report this product.
Obe-cel/ AUCATZYL® (Obecabtagene Autoleucel)
Effective November 8, 2024 - current
J3490, J3590, J9999*
Payable in Part B.
Packaged in Part A outpatient.
Code should not be billed by ASCs.
  
Code is used by Part B providers (not ASC) to report this product.
*Note: For Part B (outpatient claims), HCPCS codes J3490, J3590, J9999 are only payable when the line item has a KX modifier appended.
Collection/Handling**
Effective January 1, 2025-current
38225**
Not payable
**Tracking codes only. These steps are not paid separately.
**CPT code represents steps required to collect and prepare the genetically modified T-cells.
Collection/Handling**
Effective August 7, 2019-December 31, 2024
0537T**
Not payable
**Tracking codes only. These steps are not paid separately.
**CPT code represents steps required to collect and prepare the genetically modified T-cells.
Preparation for transport**
Effective January 1, 2025-current
38226**
Not payable
**Tracking codes only. These steps are not paid separately.
**CPT code represents steps required to collect and prepare the genetically modified T-cells.
Preparation for transport**
Effective August 7, 2019-December 31, 2024
0538T**
Not payable
**Tracking codes only. These steps are not paid separately.
**CPT code represents steps required to collect and prepare the genetically modified T-cells.
Receipt and preparation**
Effective January 1, 2025-current
38227**
Not payable
**Tracking codes only. These steps are not paid separately.
**CPT code represents steps required to collect and prepare the genetically modified T-cells.
Receipt and preparation**
Effective August 7, 2019-December 31, 2024
0539T**
Not payable
**Tracking codes only. These steps are not paid separately.
**CPT code represents steps required to collect and prepare the genetically modified T-cells.
Use the following revenue codes for billing Part A outpatient CAR T-cell therapy services:
• 0871 -- Cell Collection with CPT code 0537T (replaced with CPT code 38225 January 1, 2025)
• 0872 -- Specialized Biologic Processing and Storage, Prior to Transport with CPT code 0538T (replaced with CPT code 38226 January 1, 2025)
• 0873 -- Storage and Processing after Receipt of Cells from Manufacturer with CPT code 0539T (replaced with CPT code 38227 January 1, 2025)
• 0874 -- Infusion of Modified Cells with CPT code 0540T (replaced with CPT code 38228 January 1, 2025)
• 0891 -- Special Processed Drugs -- FDA Approved Cell Therapy with HCPCS codes Q2041, Q2042, C9073 (replaced with Q2053 April 1, 2021), C9076 (replaced with Q2054 October 1, 2021), C9081 (replaced with Q2055 January 1, 2022) , C9098 (replaced with Q2056 October 1, 2022) or C9399
Clinical trials
Part A outpatient (OPPS):
• Medicare contractors will not require NCD 110.24 REMS facility and diagnosis codes for CAR T-cell therapy CPT code 0540T (replaced with CPT code 38228 January 1, 2025) in qualifying clinical trials under NCD 310.1 billed with the NCT number for the specific trial, the Q1 clinical trial modifier for routine clinical services, CC 30, VC D4, and ICD-10 code Z00.6 clinical trial diagnosis code effective for DOS on or after August 7, 2019.
Part B outpatient:
• Medicare contractors will not require the NCD 110.24 KX modifier and diagnosis codes for qualifying clinical trials under NCD 310.1.
• These claims must be billed with the NCT number for the specific trial, the Q1 clinical trial modifier for routine clinical services, and the ICD-10 code Z00.6 clinical trial diagnosis code on the CPT code 0540T claim line effective for DOS on or after August 7, 2019 (replaced with CPT code 38228 January 1, 2025).
list item Return to key topic links list list item

Billing for Part B (outpatient) claims

Place of service
For Part B (outpatient claims), HCPCS codes Q2041, Q2042, Q2053, Q2054, Q2055, Q2056, J3490, J3590, and J9999 for CAR T-cell products will only be paid in POS 11 (office) or 49 (independent clinic). Any other place of service will be denied.
*Note: For Part B (outpatient claims), HCPCS codes Q2041, Q2042, Q2053, Q2054, Q2055, Q2056, J3490, J3590, and J9999 for CAR T-cell products are only payable when the line item has a KX modifier appended:
• When a provider submits a KX modifier on CAR T-cell therapy services, they are acknowledging the service is being submitted by or performed in an FDA REMS approved facility.
• Claims billed without the KX modifier will be denied.
Number of units
Effective for DOS on and after January 1, 2022, when entering the dollar amount for the charge of a service, providers are limited to a maximum of $99,999.99 per claim because $100,000.00 would exceed the Part B MCS field size.
The total payment for the CAR T-cell products will be divided by 10 and the provider will need to bill in 0.1-unit fractions. The provider will need to bill a total of 10 fractional units to reach the total Medicare allowed payment amount or one (1) complete unit, except as follows:
• Providers billing $499,999.99 or less would submit five claims for 0.2 fractional units per claim, for one (1) complete unit.
• For claims priced over $500,000.00, providers would bill 10 claims for 0.1 fractional units per claim.
• The total units for fractions billed shall not exceed one (1) unit.
• All claims for fractional units shall be billed with modifier LU (fractionated payment CAR T-cell therapy).
• Modifier 76 (repeat service) should also be used to bill for all subsequent fractional units.
• Claims for fractional units billed without modifier LU will be denied.
Example:
CAR T-cell product allowed payment per one unit (1.0) is $445,000:
• Claim 1 -- 0.2 units = $89,000.06
• Claim 2 -- 0.2 units = $89,000.00
• Claim 3 -- 0.2 units = $88,999.99
• Claim 4 -- 0.2 units = $88,999.98
• Claim 5 -- 0.2 units = $88,999.97
Note: Each fractional unit would be billed on a separate claim (see below). Contractors shall only pay up to one (1.0) unit per HCPCS code. Anything above one (1.0) unit will be denied.
Claim 1 example
Claims example for Claim 1 -- 0.2 units = $89,000.06
Claim 2 example (repeat process for claims 3-5)
Claim example for Claim 2 -- 0.2 units = $89,000.00
When dosage exceeds code descriptor
When the dose exceeds the code descriptor for CAR T-cell products, use HCPCS code J3490, J3590, or J9999 for the exceeded dosage. The provider would bill a total of one (1.0) unit of the Q code plus a total of one (1.0) unit of the J code and include the CAR T-cell product name and the exceeded dosage in Block 19 of the 1500 claim form or its electronic equivalent.
Example: Q2041 (Axicabtagene ciloleucel, up to 200 million autologous anti-CD19 CAR positive T-cells.)
If the provider gives 300 million cells, they will bill:
• Q2041 for 0.1 fraction $42,294.00 x10 for 200 million cells (total $422,940.00)
• J9999 for 0.2 fractions $42,294.00 x5 for 100 million cells (total $211,470.00)
Note: The FDA labels for CAR T-cell products state the maximum number of cells to be infused. The HCPCS code descriptors for Q2041, Q2042, Q2053, Q2054, Q2055, and Q2056 all align with the FDA label maximum number of cells to be infused. If a provider exceeds the HCPCS code descriptor number of cells, this is off label use. This should be extremely rare.
list item Return to key topic links list list item

Additional information

Information for the following products can be found at their respective websites
• Kymriah -- https://www.us.kymriah.com/treatment-center-locator external link
• Yescarta -- https://www.yescarta.com/lbcl/find-a-treatment-center/ external link
• Tecartus -- https://www.tecartus.com/tecartus-at-a-glance# external link
• Breyanzi -- https://www.celltherapy360.com/locations external link
• ABECMA -- https://www.celltherapy360.com/locations external link
• Carvykti -- https://www.carvyktihcp.com/treatment-centers external link
• Obe-cel/Aucatzyl -- https://www.aucatzylhcp.com/atc-locator/ external link
The necessary types of bill (TOB), detailed diagnosis and payment requirements, and claim adjustment reason code (CARC) and remittance advice remark codes (RARC) are detailed within the CMS IOM Pub. 100-04 Medicare Claims Processing Manual, Chapter 32, Section 400 external pdf file. Make sure your billing staff are aware of these changes if you bill for these services.
list item Return to key topic links list list item

Medicare Advantage claims

Medicare Advantage plans should have accounted for CAR T-cell therapy for cancer items and services in their contract year bids. Therefore, bill DOS January 1, 2021, and beyond to the Medicare Advantage plan.
Source: CR 13939 International Classification of Diseases, 10th Revision (ICD-10) and Other Coding Revisions to National Coverage
Determinations (NCDs) - July 2025 external pdf file; CR13926 Fiscal Intermediary Shared System (FISS) Changes to Automate the Application of Condition Code ZC for Chimeric Antigen Receptor (CAR) T-Cell and Other Immunotherapy Cases Involving a Clinical
Trial of a Different Product external pdf file; CMS IOM Pub. 100-04, Chapter 32, Section 400 external pdf file; CMS NCD 110.24 CAR
T-cell Therapy external link; MM12177 NCD 110.24: Chimeric Antigen Receptor (CAR) T-cell Therapy - This change request (CR) Rescinds and Fully Replaces CR 11783 external pdf file; CR12245 October 2021 HCPCS Quarterly Update Reminder external pdf file;
CR12432 October 2021 Integrated Outpatient Code Editor (I/OCE) Specifications Version 22.3 external pdf file;
CR12436 October 2021 Update of the Hospital OPPS external pdf file; MM12480 ICD-10 and Other Coding Revisions to NCDs -- April Added to sources: 2022 (CR 1 of 2) external pdf file;
MM12928 National Coverage Determination (NCD 110.24): Chimeric Antigen Receptor (CAR) T-cell Therapy external pdf file; CMS IOM Pub. 100-04 Medicare Claims Processing Manual, Chapter 32, section 68-68.4 external pdf file
First Coast Service Options (First Coast) strives to ensure that the information available on our provider website is accurate, detailed, and current. Therefore, this is a dynamic site and its content changes daily. It is best to access the site to ensure you have the most current information rather than printing articles or forms that may become obsolete without notice.